22 min listen
Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary…
Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary…
ratings:
Length:
60 minutes
Released:
Feb 23, 2024
Format:
Podcast episode
Description
Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary1).
CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary1).
Released:
Feb 23, 2024
Format:
Podcast episode
Titles in the series (100)
Dr Tom Lynch on Adjuvant EGFR TKIs in Lung Cancer and COVID-19 in Seattle: Dr Tom Lynch comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. by Oncology Today with Dr Neil Love